vs
Side-by-side financial comparison of ANAPTYSBIO, INC (ANAB) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $108.2M, roughly 1.2× ANAPTYSBIO, INC). On growth, ANAPTYSBIO, INC posted the faster year-over-year revenue change (151.1% vs 73.4%). Over the past eight quarters, ANAPTYSBIO, INC's revenue compounded faster (288.3% CAGR vs 77.0%).
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for inflammatory diseases, immuno-oncology indications, and rare disease conditions. It primarily serves the U.S. market, advancing its innovative product candidate pipeline to address unmet medical needs via rigorous research and clinical development.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
ANAB vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.2M | $129.7M |
| Net Profit | $49.6M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 61.8% | -25.0% |
| Net Margin | 45.8% | — |
| Revenue YoY | 151.1% | 73.4% |
| Net Profit YoY | 327.8% | — |
| EPS (diluted) | $1.64 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.2M | $129.7M | ||
| Q3 25 | $76.3M | $164.9M | ||
| Q2 25 | $22.3M | $114.4M | ||
| Q1 25 | $27.8M | $81.7M | ||
| Q4 24 | $43.1M | $74.8M | ||
| Q3 24 | $30.0M | $62.9M | ||
| Q2 24 | $11.0M | $54.1M | ||
| Q1 24 | $7.2M | $41.4M |
| Q4 25 | $49.6M | — | ||
| Q3 25 | $15.1M | $25.7M | ||
| Q2 25 | $-38.6M | $-12.8M | ||
| Q1 25 | $-39.3M | $-41.2M | ||
| Q4 24 | $-21.8M | — | ||
| Q3 24 | $-32.9M | $-54.8M | ||
| Q2 24 | $-46.7M | $-70.4M | ||
| Q1 24 | $-43.9M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 61.8% | -25.0% | ||
| Q3 25 | 45.5% | 15.1% | ||
| Q2 25 | -117.5% | -11.1% | ||
| Q1 25 | -99.2% | -52.2% | ||
| Q4 24 | -22.4% | -81.2% | ||
| Q3 24 | -75.8% | -89.3% | ||
| Q2 24 | -367.5% | -125.1% | ||
| Q1 24 | -587.8% | -336.5% |
| Q4 25 | 45.8% | — | ||
| Q3 25 | 19.8% | 15.6% | ||
| Q2 25 | -173.5% | -11.1% | ||
| Q1 25 | -141.6% | -50.4% | ||
| Q4 24 | -50.5% | — | ||
| Q3 24 | -109.4% | -87.1% | ||
| Q2 24 | -425.3% | -130.1% | ||
| Q1 24 | -612.0% | -328.9% |
| Q4 25 | $1.64 | $0.04 | ||
| Q3 25 | $0.52 | $0.28 | ||
| Q2 25 | $-1.34 | $-0.14 | ||
| Q1 25 | $-1.28 | $-0.47 | ||
| Q4 24 | $-0.63 | $-0.71 | ||
| Q3 24 | $-1.14 | $-0.70 | ||
| Q2 24 | $-1.71 | $-0.91 | ||
| Q1 24 | $-1.64 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.2M | $114.8M |
| Total Assets | $364.4M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.2M | $93.0M | ||
| Q3 25 | $109.8M | $110.9M | ||
| Q2 25 | $44.3M | $75.2M | ||
| Q1 25 | $98.6M | $61.9M | ||
| Q4 24 | $123.1M | $58.5M | ||
| Q3 24 | $191.6M | $36.4M | ||
| Q2 24 | $71.8M | $32.3M | ||
| Q1 24 | $53.7M | $43.3M |
| Q4 25 | $37.2M | $114.8M | ||
| Q3 25 | $-29.4M | $73.6M | ||
| Q2 25 | $-44.7M | $32.7M | ||
| Q1 25 | $34.0M | $32.8M | ||
| Q4 24 | $70.9M | $59.1M | ||
| Q3 24 | $84.4M | $-30.5M | ||
| Q2 24 | $9.9M | $15.1M | ||
| Q1 24 | $47.8M | $74.1M |
| Q4 25 | $364.4M | $605.2M | ||
| Q3 25 | $353.1M | $538.6M | ||
| Q2 25 | $335.3M | $555.3M | ||
| Q1 25 | $422.1M | $548.8M | ||
| Q4 24 | $483.8M | $594.1M | ||
| Q3 24 | $493.4M | $504.4M | ||
| Q2 24 | $427.4M | $551.1M | ||
| Q1 24 | $405.8M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $98.0M | $60.7M |
| Free Cash FlowOCF − Capex | $98.0M | — |
| FCF MarginFCF / Revenue | 90.5% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.98× | — |
| TTM Free Cash FlowTrailing 4 quarters | $19.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.0M | $60.7M | ||
| Q3 25 | $-27.4M | $14.3M | ||
| Q2 25 | $-40.2M | $5.0M | ||
| Q1 25 | $-10.7M | $-42.2M | ||
| Q4 24 | $-66.7M | $-35.7M | ||
| Q3 24 | $-10.1M | $-42.5M | ||
| Q2 24 | $-21.3M | $-40.2M | ||
| Q1 24 | $-37.3M | $-119.0M |
| Q4 25 | $98.0M | — | ||
| Q3 25 | $-27.4M | $14.2M | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-10.7M | — | ||
| Q4 24 | $-66.9M | — | ||
| Q3 24 | $-10.1M | — | ||
| Q2 24 | $-21.4M | $-40.3M | ||
| Q1 24 | $-37.3M | — |
| Q4 25 | 90.5% | — | ||
| Q3 25 | -35.9% | 8.6% | ||
| Q2 25 | -180.9% | — | ||
| Q1 25 | -38.7% | — | ||
| Q4 24 | -155.3% | — | ||
| Q3 24 | -33.7% | — | ||
| Q2 24 | -194.6% | -74.5% | ||
| Q1 24 | -519.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.3% | 0.2% | ||
| Q1 24 | 0.4% | 0.0% |
| Q4 25 | 1.98× | — | ||
| Q3 25 | -1.81× | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANAB
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
